Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP
Kyoung Min Cho, Bhumsuk Keam, Hyerim Ha, Miso Kim, Jae-Woo Jung, Woo-Jung Song, Tae Min Kim, Yoon Kyung Jeon, Hye-Ryun Kang, Dong-Wan Kim, Chul Woo Kim, Dae Seog Heo
Korean J Intern Med. 2019;34(4):885-893. Published online 2017 Nov 20 DOI: https://doi.org/10.3904/kjim.2017.036
Citations to this article as recorded by 
Infusion-Related Reactions Subsequent to Avelumab, Durvalumab, and Atezolizumab Administration: A Retrospective Observational Study
Keiko Hata, Keina Nakamura, Shinichiro Maeda, Makiko Maeda, Yasushi Fujio, Sachiko Hirobe
Clinics and Practice.2024; 14(2): 377. CrossRef
Characteristics and predictors of infusion-related reactions to rituximab in patients with B-cell non-Hodgkin lymphoma
Nour Faqeer, Rawaa Alrabie, Rand Al-Haddadin, Mohammad Ma’koseh
Journal of Chemotherapy.2023; : 1. CrossRef
Bone Marrow Infiltration Is a Distinctive Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma
Shinya Ohata, Kei Takenaka, Daisuke Sugiyama, Takeshi Sugimoto, Estella M. Matutes
Advances in Hematology.2022; 2022: 1. CrossRef
Boas Práticas na Administração do Rituximab: Revisão Integrativa da Literatura
Carmelita Almeida Rodrigues, Maria Theresa Camilo de Lima, Edvane Birelo Lopes De Domenico
Revista Brasileira de Cancerologia.2022;[Epub] CrossRef
Bone marrow involvement is a risk factor for infusion-related reactions in patients with follicular lymphoma treated by obinutuzumab
Yosuke Masamoto, Kazuki Taoka, Hiroaki Maki, Mineo Kurokawa
Annals of Hematology.2022; 101(12): 2795. CrossRef
Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial
Yuqin Song, Hui Zhou, Huilai Zhang, Wei Liu, Yuerong Shuang, Keshu Zhou, Fangfang Lv, Hao Xu, Jianfeng Zhou, Wei Li, Huaqing Wang, Hongyu Zhang, Haiwen Huang, Qingyuan Zhang, Wei Xu, Zheng Ge, Ying Xiang, Shuye Wang, Da Gao, Shun’e Yang, Jinying Lin, Lin
Advances in Therapy.2021; 38(4): 1889. CrossRef
Infusion-related reactions to rituximab: frequency, mechanisms and predictors
Franciane Paul, Guillaume Cartron
Expert Review of Clinical Immunology.2019; 15(4): 383. CrossRef
Is there a relationship between the infusion-related reaction and effect of rituximab in the treatment of patients with diffuse large B-cell lymphoma?
Sang-Gon Park
The Korean Journal of Internal Medicine.2019; 34(4): 775. CrossRef
Rituximab
Reactions Weekly.2019; 1772(1): 285. CrossRef